Tonix Sues Dr. Reddy's on TONMYA Patents, Triggering 30-Month FDA Approval Stay
TNXP is trading near its 52-week low of $2.9 (3.1% above the low) on elevated volume (2.4× avg).
Summary
Tonix filed a patent infringement suit against Dr. Reddy's over its TONMYA ANDA, securing a statutory stay of final FDA approval for up to 30 months. The stay shields the company's only meaningful revenue product while the case plays out.
Key Events · Legal and Risk Events · TNXP
-
Tonix Sues Dr. Reddy's Over TONMYA Patents
Complaint filed November 13, 2026 in the U.S. District Court for the District of New Jersey, alleging the ANDA infringes certain Orange Book-listed patents covering TONMYA 2.8 mg sublingual tablets.
-
30-Month Stay Blocks Generic Approval
The timely filing triggers a statutory stay of final FDA approval of DRL's ANDA for up to 30 months, subject to exceptions and court orders.
-
Four Patents Under Attack
DRL's Paragraph IV certification challenges U.S. Patent Nos. 9,636,408, 9,956,188, 10,117,936 and 10,864,175; Tonix seeks an approval date no earlier than expiry of the last to expire asserted patent.
-
Revenue Concentration Raises the Stakes
TONMYA net sales were $15.0 million in Q3 with total product revenue of $17.2 million, against a $53.3 million net loss and cash management says lasts into early Q3 2027.
Analysis · TNXP · Life Sciences
Tonix has now formally sued Dr. Reddy's in New Jersey federal court over the Paragraph IV ANDA that challenges all four Orange Book patents on TONMYA, its lead commercial drug. The practical payoff is procedural: a timely complaint buys a statutory stay of final FDA approval of the generic for up to 30 months, so no generic can launch while the case runs unless a court lifts the stay or Tonix loses. That matters because TONMYA is essentially the whole revenue story — $15.0 million of net sales in Q3 against a $53.3 million quarterly net loss and cash that management says runs only into early Q3 2027. The stay protects the franchise near-term, but it is not a win: the patents can still be found invalid, unenforceable or not infringed, and litigation costs and management distraction are real.
How filings like this one have moved
In the 30 days to Nov 15, 2026, 37.5% of the 3715 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TNXP was trading at $2.99 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $58.5M. The 52-week trading range was $2.90 to $20.56. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.